Wettig Thane reported FGEN

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001815638-25-000005

Machine-readable

Structured copy

Timestamps

Event (reported)

Dec 6, 2025

Published

Dec 9, 2025

Ingested by INSIDER

Nov 5, 04:28 UTC

Last re-read

Nov 5, 04:28 UTC

Extracted facts

Filer

Wettig Thane

Role

Director, CEO

Transaction

Tax withholdingAs filed: “F”

Asset

FIBROGEN INC

Ticker

FGEN

Shares

259

Price per share

$8.42

Value

$2,181

Execution date (reported)

Dec 6, 2025

Owned after transaction

24.7K shares

Days from execution to publication

3

Calculation

What this establishes

Wettig Thane filed this Form 4 reporting a tax withholding of FGEN on Dec 6, 2025. It became public on Dec 9, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director, CEO

Wettig Thanecik:0001815638

Issuer

KYNTRA BIO, INC.cik:0000921299

Revision history · 0

No field has changed since this record was first ingested.